Skip to main content

Advertisement

SpringerLink
Log in

Does intravesical atropine have equivalent efficacy to oral oxybutynin in the treatment of detrusor overactivity?

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (5A Suppl): 33–46

    Article  CAS  Google Scholar 

  2. Haferkamp A and Hohenfellner M (2006) Intravesikale therapie des overactive-bladder-syndroms [German]. Urologe 45: 1283–1288

    Article  CAS  Google Scholar 

  3. Araki I et al. (2003) Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 169: 1384–1387

    Article  Google Scholar 

  4. Litwiller SE et al. (1999) Multiple sclerosis and the urologist. J Urol 161: 743–757

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Tamsin Osborne, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. Neuro-Urology and Voiding Dysfunction in the Department of Urology, AM Arisco is a clinical instructor and is completing her Fellowship in Female Urology, University of Texas Health Science Center, San Antonio, TX, USA.,

    Amy M Arisco

  2. and Associate Professor and Vice Chairman in the Department of Urology, SR Kraus is Head of the Section of Female Urology, Neuro-Urology and Voiding Dysfunction, University of Texas Health Science Center, San Antonio, TX, USA.,

    Stephen R Kraus

Authors
  1. Amy M Arisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen R Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen R Kraus.

Ethics declarations

Competing interests

SR Kraus received research support from the National Institutes of Health. He is a Consultant, Speaker and receives research support from Pfizer; he is a speaker for Novartis and is a speaker and receives research support from Astellas.

AM Arisco declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arisco, A., Kraus, S. Does intravesical atropine have equivalent efficacy to oral oxybutynin in the treatment of detrusor overactivity?. Nat Rev Urol 4, 538–539 (2007). https://doi.org/10.1038/ncpuro0910

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0910

  • Springer Nature Limited

Search

Navigation